Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan

J V Lacey Jr, O B Ioffe, B M Ronnett, B B Rush, D A Richesson, N Chatterjee, B Langholz, A G Glass, M E Sherman, J V Lacey Jr, O B Ioffe, B M Ronnett, B B Rush, D A Richesson, N Chatterjee, B Langholz, A G Glass, M E Sherman

Abstract

Classifying endometrial hyperplasia (EH) according to the severity of glandular crowding (simple hyperplasia (SH) vs complex hyperplasia (CH)) and nuclear atypia (simple atypical hyperplasia (SAH) vs complex atypical hyperplasia (CAH)) should predict subsequent endometrial carcinoma risk, but data on progression are lacking. Our nested case-control study of EH progression included 138 cases, who were diagnosed with EH and then with carcinoma (1970-2003) at least 1 year (median, 6.5 years) later, and 241 controls, who were individually matched on age, date, and follow-up duration and counter-matched on EH classification. After centralised pathology panel and medical record review, we generated rate ratios (RRs) and 95% confidence intervals (CIs), adjusted for treatment and repeat biopsies. With disordered proliferative endometrium (DPEM) as the referent, AH significantly increased carcinoma risk (RR=14, 95% CI, 5-38). Risk was highest 1-5 years after AH (RR=48, 95% CI, 8-294), but remained elevated 5 or more years after AH (RR=3.5, 95% CI, 1.0-9.6). Progression risks for SH (RR=2.0, 95% CI, 0.9-4.5) and CH (RR=2.8, 95% CI, 1.0-7.9) were substantially lower and only slightly higher than the progression risk for DPEM. The higher progression risks for AH could foster management guidelines based on markedly different progression risks for atypical vs non-atypical EH.

Figures

Figure 1
Figure 1
Identification, assessment, and eligibility status of potential cases and potential controls.

References

    1. ACOG (2005) ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 106: 413–425
    1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366: 491–505
    1. Baak JP, Mutter GL, Robboy S, Van Diest PJ, Uyterlinde AM, Orbo A, Palazzo J, Fiane B, Løvslett K, Burger C, Voorhorst F, Verheijen RH (2005) The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 103: 2304–2312
    1. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10–17
    1. Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK (2002) Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. BJOG 109: 313–321
    1. Clark TJ, Neelakantan D, Gupta JK (2006) The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol 125: 259–264
    1. Cologne JB, Sharp GB, Neriishi K, Verkasalo PK, Land CE, Nakachi K (2004) Improving the efficiency of nested case–control studies of interaction by selecting controls using counter matching on exposure. Int J Epidemiol 33: 485–492
    1. Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP (2000) The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 89: 1765–1772
    1. Feldman S, Cook EF, Harlow BL, Berkowitz RS (1995) Predicting endometrial cancer among older women who present with abnormal vaginal bleeding. Gynecol Oncol 56: 376–381
    1. Feldman S, Shapter A, Welch WR, Berkowitz RS (1994) Two-year follow-up of 263 patients with post/perimenopausal vaginal bleeding and negative initial biopsy. Gynecol Oncol 55: 56–59
    1. Ferenczy A, Gelfand M (1989) The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 160: 126–131
    1. Horn LC, Meinel A, Handzel R, Einenkel J (2007) Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann Diagn Pathol 11: 297–311
    1. Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J (2004) Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 14: 348–353
    1. Karamursel BS, Guven S, Tulunay G, Kucukali T, Ayhan A (2005) Which surgical procedure for patients with atypical endometrial hyperplasia? Int J Gynecol Cancer 15: 127–131
    1. Keshavarz H, Hillis SD, Marchbanks PA (2002) Hysterectomy surveillance – United States, 1994–1999. MMWR 51(SS05): 1–8
    1. Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia. A long-term study of ‘untreated’ hyperplasia in 170 patients. Cancer 56: 403–412
    1. Langholz B (2007) Use of cohort information in the design and analysis of case–control studies. Scand J Stat 34: 120–136
    1. Langholz B, Clayton D (1994) Sampling strategies in nested case–control studies. Environ Health Perspect 102(Suppl 8): 47–51
    1. Langholz B (2006) Batch Quota Sampling. Technical Report 173. Biostatistics Division, Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
    1. Lindahl B, Willen R (1994) Spontaneous endometrial hyperplasia. A prospective, 5 year follow-up of 246 patients after abrasio only, including 380 patients followed-up for 2 years. Anticancer Res 14: 2141–2146
    1. Marsden DE, Hacker NF (2001) Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol 15: 393–405
    1. Mazur MT (2005) Endometrial hyperplasia/adenocarcinoma. A conventional approach. Ann Diagn Pathol 9: 174–181
    1. McCluggage WG (2006) My approach to the interpretation of endometrial biopsies and curettings. J Clin Pathol 59: 801–812
    1. Montgomery BE, Daum GS, Dunton CJ (2004) Endometrial hyperplasia: a review. Obstet Gynecol Surv 59: 368–378
    1. Mutter GL (2000) Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 76: 287–290
    1. Mutter GL (2002) Diagnosis of premalignant endometrial disease. J Clin Pathol 55: 326–331
    1. Pettersson B, Adami HO, Lindgren A, Hesselius I (1985) Endometrial polyps and hyperplasia as risk factors for endometrial carcinoma. A case–control study of curettage specimens. Acta Obstet Gynecol Scand 64: 653–659
    1. Randall TC, Kurman RJ (1997) Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90: 434–440
    1. Shutter J, Wright Jr TC (2005) Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia. Int J Gynecol Pathol 24: 313–318
    1. Silverberg SG (2000) Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod Pathol 13: 309–327
    1. Soslow RA (2006) Problems with the current diagnostic approach to complex atypical endometrial hyperplasia. Cancer 106: 729–731
    1. Tabata T, Yamawaki T, Yabana T, Ida M, Nishimura K, Nose Y (2001) Natural history of endometrial hyperplasia. Study of 77 patients. Arch Gynecol Obstet 265: 85–88
    1. Terakawa N, Kigawa J, Taketani Y, Yoshikawa H, Yajima A, Noda K, Okada H, Kato J, Yakushiji M, Tanizawa O, Fujimoto S, Nozawa S, Takahashi T, Hasumi K, Furuhashi N, Aono T, Sakamoto A, Furusato M (1997) The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. J Obstet Gynaecol Res 23: 223–230
    1. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke II JJ, Alberts D, Curtin J (2006) Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106: 812–819
    1. Valenzuela P, Sanz JM, Keller J (2003) Atypical endometrial hyperplasia: grounds for possible misdiagnosis of endometrial adenocarcinoma. Gynecol Obstet Invest 56: 163–167
    1. Wagner EH, Greene SM, Hart G, Field TS, Fletcher S, Geiger AM, Herrinton LJ, Hornbrook MC, Johnson CC, Mouchawar J, Rolnick SJ, Stevens VJ, Taplin SH, Tolsma D, Vogt TM (2005) Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr 2005: 3–11
    1. Zaino RJ (2000) Endometrial hyperplasia: is it time for a quantum leap to a new classification? Int J Gynecol Pathol 19: 314–321
    1. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, Gallup DG (2006) Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106: 804–811

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi